Nadeem Riaz
@xrtGenomics
Physician/Scientist. Head and Neck Oncologist (radiation) & Computational Biologist. Interests in cancer genomics, immunotherapy & DNA repair. @MSKCancerCenter
🧵 Paradigm-buster just out: ATM-deficient tumors stay cold ❄️—unlike other DNA-repair defects—so PD-1 blockade alone (or with ATRi) falls flat. We mapped the biology in mice + patients. Paper in @JITCancer now (link below) -- #ImmunoOncology #DNArepair @OncoAlert (1/9)
This R packages can transform any plot using color pallets from painting at the Museum of Modern Art in New York github.com/BlakeRMills/Me…
How well does AI based assessment of mutations in DNA repair genes in cancer work -- we took a look 👇 great work by @ShuYazaki and team.
1/ 🧬Our paper is out @JCOPO_ASCO! We tested AlphaMissense(an AI tool for predicting the pathogenicity of missense mutations), across DNA damage repair genes in cancer. Key finding: accuracy varies dramatically by gene - crucial for clinical use! ➡️ ascopubs.org/doi/full/10.12…
Oof. Polygenic scores for IQ lose 75% of their explained variance when adding family controls, even worse than the attenuation for Educational Attainment. These are the scores Silicon Valley is using to select embryos 😬. A few thoughts on this study ...
Yeah no amount of assortative mating can explain this gap. icajournal.scholasticahq.com/article/140654…
In @JCO_ASCO, our reflections on the timely ASCO TORS guideline @imrtlee @xrtGenomics 💡Encourage MR (r/o T4+ENE) & PET (r/o contra in N+) 💡Promote ND qual (min # nodes), ⬇️ bilat ND (morbid) 💡Caution re: ❌chemo 2/2 ENE degree & real-world use of frozens re margin status
Led by Drs. Zakeri & @imrtlee, we report early @MSK_RadOnc exp w/ 40 Gy ENI + CCRT for larynx, HPX, p16- OPX + CUP, 97.3% platinum, no uninvolved 1B+5 ☑️73 pts, f/u 23 months ✅no solitary elective failures, all LRF include 70 Gy failures ✅good QoL 👉 shorturl.at/CKA6W
👀Using an autonomous agent based on o3-mini and GPT-4.1, a team from Harvard, MIT & other institutions reproduced and updated an entire issue of Cochrane Reviews in two days… saving 12 person-years of work! The AI reviews captured more papers & were more accurate than humans.
🚨🚨🚨 pembro in localized hnscc is finally approved !
BREAKING🚨: @US_FDA Approves Perioperative Pembrolizumab for Resectable, Locally Advanced HNSCC #oncology onclive.com/view/fda-appro…
What changed in E3311 long-term data? ✔️Transoral surgery + 50 Gy = durable control in intermediate-risk HPV+ OPC ✔️No OS or PFS difference by smoking or subsite ⚠️Observation alone in N1? Late recurrences → risky 🔑Pathologic risk-based adjuvant therapy works
AI-based tumor board! This space is evolving so fast.... this is a great paper on whats about to come very soon, and very widely....
Very happy to share our new paper on LLM-based tumor board agents. Submitted August 2024, published in @NatureCancer today ☺️ Led by @Dykex6 nature.com/articles/s4301…
Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but rather the body’s circadian rhythm and physiology: 1: Exercise after surgery 2: Checkpoint inhibitors in the morning
👋🚨NIVOPOSTOP GORTEC #ASCO25 ‼️adj nivo x1 ➡️concurrent nivo-CRT➡️ nivo improved DFS (mostly LRC). Waiting for OS results.
🔔Exciting results of adj cancer directed vaccines for high risk respected HPVneg HNSCC. #ASCO25 Congrats to the investigators for this novel work.
Remarkable efforts to obtain on-treatment tissue to study TME. CRT with sequential pembro *might* be more favorable than concurrent pembro. ascopubs.org/doi/pdf/10.120… @KaramLab @xrtGenomics @DavidSherMD @aadel_chaudhuri @ScottBratman
Interesting data on some exceptional respones to Lu-PSMA in ATM-mutated cancers. In line with EBRT data.
Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative…
📢Safety and potential efficacy of PARP inhibitor with #radiotherapy in homologous recombination defective triple negative #breastcancer‼️ Maybe radiation/drug combos are slowly but surely coming? @IJROBP @xrtGenomics @KrauseProf #radbio #bcsm redjournal.org/article/S0360-…
New #JITC article: The cold immunological landscape of ATM-deficient cancers bit.ly/4k2rNfY @isaacpei @deadoc80 @xrtGenomics
So excited to share our latest work with Sarat Chandarlapaty, @antoniomarraMD, Andrea Gazzo @MSKCancerCenter out today in @NatureGenet! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/ nature.com/articles/s4158…
We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Program in August. This is a full-circle moment for Dr. Minn, a renowned physician-scientist, who completed his postdoctoral training with Dr. Joan Massagué,…
Excited to share our recent @Nature paper! nature.com/articles/s4158… Tremendous collaborative effort from @UCCancerCenter @UChicago @UChicagoRadonc @rweichselbaum